[go: up one dir, main page]

WO2001079539A3 - Procede d'utilisation de constructions transfectables composees de luciferase et du promoteur du gene periode 1 humain pour l'identification de nouveaux agents actifs ayant un effet sur le rythme jour/nuit et sur le sommeil - Google Patents

Procede d'utilisation de constructions transfectables composees de luciferase et du promoteur du gene periode 1 humain pour l'identification de nouveaux agents actifs ayant un effet sur le rythme jour/nuit et sur le sommeil Download PDF

Info

Publication number
WO2001079539A3
WO2001079539A3 PCT/EP2001/004383 EP0104383W WO0179539A3 WO 2001079539 A3 WO2001079539 A3 WO 2001079539A3 EP 0104383 W EP0104383 W EP 0104383W WO 0179539 A3 WO0179539 A3 WO 0179539A3
Authority
WO
WIPO (PCT)
Prior art keywords
transfectable
promotor
luciferase
gene
sleep
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/004383
Other languages
German (de)
English (en)
Other versions
WO2001079539A2 (fr
WO2001079539A9 (fr
Inventor
Dirk Motzkus
Erik Maronde
Sabine Loumi
Urs Albrecht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IPF Pharmaceuticals GmbH
Original Assignee
IPF Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IPF Pharmaceuticals GmbH filed Critical IPF Pharmaceuticals GmbH
Priority to AU2001268973A priority Critical patent/AU2001268973A1/en
Publication of WO2001079539A2 publication Critical patent/WO2001079539A2/fr
Publication of WO2001079539A3 publication Critical patent/WO2001079539A3/fr
Anticipated expiration legal-status Critical
Publication of WO2001079539A9 publication Critical patent/WO2001079539A9/fr
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2864—Sleep disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une construction transfectable composée du promoteur du gène de période 1 humain et de luciférase (hPER1-luc).
PCT/EP2001/004383 2000-04-18 2001-04-18 Procede d'utilisation de constructions transfectables composees de luciferase et du promoteur du gene periode 1 humain pour l'identification de nouveaux agents actifs ayant un effet sur le rythme jour/nuit et sur le sommeil Ceased WO2001079539A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001268973A AU2001268973A1 (en) 2000-04-18 2001-04-18 Method for using transfectable constructions from luciferase and from the promotor of the human period 1 gene for identifying novel active substances that influence the day/night rhythm and sleep

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10019360.9 2000-04-18
DE10019360 2000-04-18

Publications (3)

Publication Number Publication Date
WO2001079539A2 WO2001079539A2 (fr) 2001-10-25
WO2001079539A3 true WO2001079539A3 (fr) 2002-05-10
WO2001079539A9 WO2001079539A9 (fr) 2003-05-22

Family

ID=7639288

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/004383 Ceased WO2001079539A2 (fr) 2000-04-18 2001-04-18 Procede d'utilisation de constructions transfectables composees de luciferase et du promoteur du gene periode 1 humain pour l'identification de nouveaux agents actifs ayant un effet sur le rythme jour/nuit et sur le sommeil

Country Status (2)

Country Link
AU (1) AU2001268973A1 (fr)
WO (1) WO2001079539A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1248107A3 (fr) * 2001-03-22 2002-10-16 IPF Pharmaceuticals GmbH Procédé et appareil de criblage à résolution temporelle
CN114306607A (zh) * 2021-12-31 2022-04-12 中国人民解放军军事科学院军事医学研究院 初级纤毛调控生物节律及其相关应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003549A1 (fr) * 1996-07-18 1998-01-29 The General Hospital Corporation Regions regulatrices du gene du recepteur 1a de la melatonine et utilisations correspondantes
WO1999012952A1 (fr) * 1997-09-09 1999-03-18 Research Development Foundation Gene de mammifere de type rythme circadien

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003549A1 (fr) * 1996-07-18 1998-01-29 The General Hospital Corporation Regions regulatrices du gene du recepteur 1a de la melatonine et utilisations correspondantes
WO1999012952A1 (fr) * 1997-09-09 1999-03-18 Research Development Foundation Gene de mammifere de type rythme circadien

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHEN, D, BUCHANAN, GF, DING JM, HANNIBAL, J & GILLETTE MU: "Pituitary adenylyl cyclase-activating peptide: A pivotal modulator of glutamatergic regulation of the suprachiasmatic circadian clock", PROCEEDINGS OF THE NATIONAL ADCADEMY OF SCIENCE USA, vol. 96, no. 23, 9 November 1999 (1999-11-09), pages 13468 - 13473, XP002181664 *
DATABASE GENBANK *
GEKAKIS N, STAKNIS D, NGUYEN HB, DAVIS FC, WILSBACHERLD, KING DP, TAKAHASHI JS & WEITZ CJ: "Role of the CLOCK Protein in the Mammalian Circadian Mechanism", SCIENCE, vol. 280, 5 June 1998 (1998-06-05), pages 1564 - 1569, XP002181665 *
HANNIBAL J, DING JM, CHEN D, FAHRENKRUG J, LARSEN PJ, GILLETTE MU & MIKKELSEN JD: "Pituitary Adenylate Cyclase-Activating Peptide (PACAP) in the Retinohypothalamic Tract: A Potential Daytime Regulator of the Biological Clock", THE JOURNAL OF NEUROSCIENCE, vol. 17, no. 7, 1 April 1997 (1997-04-01), pages 2637 - 2644, XP002181663 *
MOTZKUS D, MARONDE E, GRUNENBERG U, LEE CC, FORSSMANN W-G & ALBRECHT U: "The human PER1 gene is transcriptionally regulated by multiple signaling pathways", FEBS LETTERS, vol. 486, no. 3, 30 November 2000 (2000-11-30), pages 315 - 319, XP001018855 *
SUN Z S ET AL: "RIGUI, A PUTATIVE MAMMALIAN ORTHOLOG OF THE DROSOPHILA PERIOD GENE", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 90, no. 6, 19 September 1997 (1997-09-19), pages 1003 - 1011, XP002915075, ISSN: 0092-8674 *
TARUSCIO D ET AL: "The human Per1 gene: genomic organization and promoter analysis of the first human orthologue of the Drosophila period gene", GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, vol. 253, no. 2, 8 August 2000 (2000-08-08), pages 161 - 170, XP004215719, ISSN: 0378-1119 *

Also Published As

Publication number Publication date
AU2001268973A1 (en) 2001-10-30
WO2001079539A2 (fr) 2001-10-25
WO2001079539A9 (fr) 2003-05-22

Similar Documents

Publication Publication Date Title
WO2001079458A3 (fr) Polypeptides ayant une activite d'haloperoxidase
WO2001079459A3 (fr) Polypeptides ayant une activite d'haloperoxydase et acides nucleiques qui les codent
DE69633947D1 (de) Zwischenprodukte zur Herstellung von Metallproteinasehemmern
DE60042550D1 (de) Mutierte varianten des insulin-ähnlichen wachstumsfaktor i (igf-i)
DE69829207D1 (de) Vierkammer-herzschrittmachersystem zur optimierung des herzzeitvolumens
AU8604898A (en) Transgenic plants tolerant of salinity stress
AU2001231091A1 (en) Identification of genetic components of drug response
AU9107598A (en) Succinic acid production and purification
AU6099100A (en) Ultra-rugged i.c. sensor and method of making the same
AU2001290063A1 (en) Time keeping system and watch
AU3549697A (en) Extracting particles produced by the treating of human or animal nails
DE69812784D1 (de) Zusammensetzung zur Vorbeugung und Beseitigung von Pflanzenkrankheiten
DE69818026D1 (de) Wässrige suspension zur nasalen verabreichung von loteprednol
AU2002213422A1 (en) Synthesis of 2-hydroxymethylglutamic acid and congeners thereof
PL313858A1 (en) Method of making inactive or killing microorganisms
DE69420229D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
AU4940296A (en) Genetic modification of plants
WO2001079539A3 (fr) Procede d'utilisation de constructions transfectables composees de luciferase et du promoteur du gene periode 1 humain pour l'identification de nouveaux agents actifs ayant un effet sur le rythme jour/nuit et sur le sommeil
DE69528855D1 (de) Pyrazolin-Derivate zur Bekämpfung von Pflanzenkrankheiten
WO2001046392A3 (fr) Substances
DE69812861D1 (de) Walzwerk zur herstellung von axialsymmetrischen teilen
AUPP271198A0 (en) New variants on low-latency convolution - smooth updating of filter response using crossfades
AU2002366072A1 (en) Systems and methods relating to determining the desirability of and recording programming events
WO2003030936A1 (fr) Medicaments contre des maladies liees au style de vie ou la cibophobie et methode de criblage de ces derniers
AU4176200A (en) Novel genetic suppressor elements and methods of making the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

COP Corrected version of pamphlet

Free format text: PAGES 1/7 AND 2/7, DRAWINGS, REPLACED BY NEW PAGES 1/7 AND 2/7; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP